Objective: As the absence of Ab-related memory decline in APOE e4 noncarriers may be due to the relative brevity of previous studies, we aimed to characterize Ab-related cognitive decline over 72 months in APOE e4 carriers and noncarriers who were cognitively normal (CN).
In cognitively normal (CN) older adults, both high amyloid (Ab1) and carriage of the APOE e4 allele increase risk for cognitive decline and dementia of the Alzheimer type, [1] [2] [3] although the interaction between Ab1 and e4 carriage in the preclinical stages of Alzheimer disease (AD) is not understood. Clinical studies show substantial cognitive decline over 54 months in Ab1 CN e4 carriers, particularly in episodic memory, compared to Ab2 CN e4 noncarriers. However, cognitive decline has not been observed in Ab1 CN e4 noncarriers [4] [5] [6] suggesting that in preclinical AD, Ab-related cognitive decline is delayed in the absence of e4. This hypothesis is consistent with observations from epidemiologic studies that in the absence of APOE e4, the average age at which dementia is classified clinically is delayed by approximately 8 years. 7, 8 However, the nature and length of any such delay in preclinical AD is unknown.
This study aimed to characterize the rate of Ab-related cognitive decline over 72 months in CN older adults who were e4 carriers and noncarriers. We hypothesized that compared to Ab2 CN e4 noncarriers and Ab1 CN e4 noncarriers, Ab1 CN e4 carriers would show greater cognitive decline and higher rates of progression to mild cognitive impairment (MCI) over 72 months. METHODS Participants. CN older adults (n 5 767) volunteered to participate in the Australian Imaging, Biomarkers and Lifestyle Study (AIBL), for which details of the recruitment and classification of cognitive health has been previously detailed. 9, 10 Briefly, participants were excluded from AIBL if they had a previous confirmed diagnosis of schizophrenia, Parkinson disease, sleep apnea, depression (e.g., Geriatric Depression Scale score of 6 or greater), cancer (except basal cell skin carcinoma) in the last 2 years, or symptomatic stroke or uncontrolled diabetes, or current alcohol use exceeded 4 standard drinks per day for men or 2 per day for women. This study focused on a subsample of CN older adults (n 5 423) who had undergone Ab neuroimaging with PET and APOE genotyping. The demographic and clinical characteristics of the total and PET subsample are shown and compared in table 1.
All available neuropsychological, psychiatric, and medical information for participants on all assessments were reviewed by an expert clinical panel to determine whether individuals' classification remained as CN or whether they met diagnostic classification for MCI 11, 12 or AD. 13 Clinical classifications were blinded to data obtained from Ab imaging at all visits.
Standard protocol approvals, registrations, and patient consents. The AIBL study was approved by the ethics committees of Austin Health, St. Vincent's Health, Hollywood Private Hospital, and Edith Cowan University. These institutions also ensured compliance of all study protocols. 9 Informed consent was provided in writing prior to participation in any study procedure.
Assessments. PET neuroimaging and APOE e4 genotyping.
PET Ab imaging was conducted using one of 3 radioligands: Pittsburgh compound B (PiB), florbetapir, or flutemetamol. The acquisition protocol for each radioligand has been detailed previously. 10, 14, 15 Briefly, a 30-minute acquisition was started 40 minutes after PiB injection, and 20-minute acquisitions were performed 50 minutes after florbetapir injection and 90 minutes after flutemetamol injection. For PiB acquisition, standardized uptake value (SUV) data for key regions of interest were summed and normalized to the cerebellar cortex SUV. This resulted in a region-to-cerebellar ratio, which was termed SUV ratio (SUVR). For florbetapir, SUVR was generated using the whole cerebellum as the reference region, 16 and for flutemetamol, the pons was used as the reference region. Consistent with previous studies, Ab status was classified as either low (Ab2) or high (Ab1). For PiB, an SUVR threshold $1.5 was used. 10, 15 For florbetapir and flutemetamol, an SUVR threshold of $1.1 and $0.62 were employed to discriminate between Ab2 and Ab1, in accord with results of phase III studies. 16 An 80-mL blood sample was taken from each participant, a sample of which was forwarded for DNA extraction using either QIAamp DNA blood Midi or Maxi kits (Qiagen, Venlo, Netherlands) in accord with the protocol provided by the manufacturer. APOE genotype was determined through TaqMan genotyping assays (Life Technologies, Carlsbad, CA) for rs7412 (Assay ID: C_904973_10) and rs429358 (Assay ID: C_3084793_20) on a QuantStudio 12K-Flex real-time PCR system (Applied Biosystems, Foster City, CA) using the TaqMan GTXpress Master Mix (Life Technologies) methodology per manufacturer's instructions.
Neuropsychological testing. To compute composite cognitive scores, first, each outcome measure on each neuropsychological test was standardized using the baseline mean and SD for the total CN group. Composite scores were then formed by averaging standardized scores for episodic memory (California Verbal Learning Test, Second Edition delayed recall, Logical Memory delayed recall, and Rey Complex Figure Test executive function (Category Fluency Fruit/Furniture Switching and Letter Fluency); language (Boston Naming Test and Category Fluency Animals/Boys' Names total score); and attention (Digit Symbol and Digit Span). We have previously detailed the rationale, development, and validation for each cognitive composite score. 17, 18 Procedure. Upon enrollment into AIBL, all participants underwent detailed medical, psychiatric, and neuropsychological assessment. These same assessments were repeated at 18-month intervals. In this study, we report PET neuroimaging and APOE e4 genotyping data obtained at a single assessment, and neuropsychological data obtained at the baseline, 18-, 36-, 54-, and 72-month assessments.
Data analysis. To examine relationships between group (Ab2 CN e4 noncarrier, Ab2 CN e4 carrier, Ab1 CN e4 noncarrier, Ab1 CN e4 carrier) and time (baseline and 18, 36, 54, and 72 months of follow-up) for each composite cognitive score, we conducted a series of analyses using linear mixed effects models (LMMs) with an unstructured covariance matrix and maximum likelihood estimation. The linear mixed modeling approach was employed because it is robust to missing data (see figure 1 for number of participants who withdrew from the study or had died), because it can model both fixed and random effects, thus accounting for multiple sources of variability, and because it provides improved estimates of random effects (within-subject coefficients) in prospective studies. For each LMM, the cognitive composite score was the dependent variable. Group, time, and the interaction between group and time were specified as fixed factors; participant was specified as a random factor; and age and anxiety symptoms as the only covariates. Group mean slopes were computed for each cognitive composite score to reflect estimates of the rate of cognitive change over time. Where LMMs indicated an interaction between group and time as statistically significant, estimates of slope in the Ab2 CN e4 carriers, Ab1 CN e4 noncarriers, and Ab1 CN e4 carriers were compared to that in the Ab2 CN e4 noncarriers. Differences between slopes were expressed using Cohen d. To provide context for any differences in memory decline observed between study groups, a criterion for clinically significant memory impairment was defined as performance ,1.5 SD below that of Ab2 e4 noncarriers. The amount of time estimated for memory performance to reach this criterion was computed for each study group based on LMM-derived linear functions.
RESULTS Demographic and clinical characteristics.
There were no significant differences between the demographic and clinical characteristics of the total CN sample and the PET subsample, as the 95% confidence intervals (CI) for each outcome measure overlap (table 1) . Statistically significant differences between Ab/e4 groups were observed for age and anxiety symptoms at baseline (table 1) . Consequently, age and anxiety symptoms were entered as covariates in the LMMs. Groups did not differ significantly on any other demographic or clinical characteristic at baseline.
Effect of Ab and e4 on cognitive change. Table 2 provides a summary of the group mean slopes for each cognitive composite for each Ab/e4 group. Compared to Ab2 CN e4 noncarriers, Ab1 CN e4 carriers showed a significantly increased decline on all cognitive composites, and the magnitudes of these differences were moderate to large (figures 2 and 3). However, compared to Ab1 CN e4 noncarriers, Ab1 CN e4 carriers showed a significantly increased decline only on the measure of episodic memory, and the magnitude of this difference was large. Compared to Ab2 CN e4 noncarriers, Ab1 CN e4 noncarriers also showed a faster rate of decline for the measures of episodic memory, language, and executive function ( figure 3 ). The rate of decline in episodic memory in Ab1 CN e4 carriers indicated that the memory performance of this group would be severe enough to meet the criterion for clinically significant impairment in approximately 10 years (95% CI 6-18 years) as opposed to 27 years (95% CI 10-45 years) in Ab1 CN e4 noncarriers. Compared to Ab1 CN e4 noncarriers, Ab1 CN e4 carriers showed an increased rate of decline only for episodic memory ( figure 3 ). Group mean slopes of Ab2 CN e4 noncarriers and Ab2 CN e4 carriers did not differ significantly on any cognitive composite.
Effect of Ab and e4 on rates of disease progression. At the 72-month assessment, the rate of clinical reclassification from CN to MCI/AD was significantly greater for Ab1 CNs (18%) than for Ab2 CNs (6%) (x 2 5 9.91, p , 0.001, Cramér V 5 0.17) (figure 1). However, while the rate of clinical reclassification from CN to MCI/AD was greater in Ab1 CN e4 carriers (22%) than Ab1 CN e4 noncarriers (15%), this difference was not large enough to reach statistical significance (x 2 5 0.49, p 5 0.49, Cramér V 5 0.09). DISCUSSION The hypothesis that Ab1 CN e4 carriers would show an increased rate of cognitive decline and greater rates of progression to MCI/AD compared to Ab2 CN e4 noncarriers and Ab1 CN e4 noncarriers was supported. Compared to Ab2 CN noncarriers, Ab1 CN e4 carriers showed decline in all cognitive domains, although this was greatest for episodic memory (figures 2 and 3). Compared to Ab1 CN e4 noncarriers, Ab1 CN e4 carriers also showed a faster rate of decline in episodic memory, which was, by convention, also large in magnitude (table 2, figure 2 ). The exacerbation of Ab-related memory decline by e4 is both consistent with, and extends, the results of previous analyses of AIBL data over shorter periods 5, 6 and also from other cohorts, 4 that e4 carriage increases the rate of Ab-related memory decline over 18 to 54 months. It is also consistent with animal studies that show that in the presence of Ab1, the apoE4 isoform causes cognitive impairment. No such impairment is observed in the presence of the apoE3 isoform. 8, 19 The current results also characterize the much slower rate of development of Ab-related memory decline in CN older adults who do not carry the APOE e4 allele. Previous analyses of data from Ab1 CN older adults in AIBL conducted over shorter periods (e.g., 36 months) have observed that Ab-related cognitive decline is restricted to episodic memory. 17 In the current study, cognitive decline in Ab1 CN older adults extended to executive function, language, and attention, albeit with more subtle trajectories (table 2). The detection of Ab-related decline in domains beyond memory, observed in the current study, was due to the larger sample size in this study and because individuals had been assessed over a much longer time interval than previously. In this context, the observation that exacerbation of Ab-related cognitive decline by APOE e4
was specific to episodic memory confirms the centrality of episodic memory dysfunction to early AD. It is also consistent with previous studies that also observed that Ab-related cognitive decline in preclinical AD occurs only for APOE e4 carriers and only for episodic memory. 4, 5 With a longer study period, Abrelated decline in cognitive functions other than memory will become evident in Ab1 CN e4 noncarriers. Previously, we have expressed the relevance of Abrelated memory decline in CN older adults as the time required for a declining memory trajectory to reach a level of clinically significant memory impairment, that is, memory impairment that would warrant consideration of a diagnosis of MCI. 12 In this study, clinically significant memory impairment was defined as performance that is less than 1.5 standard deviations from matched controls (figure 2, dashed horizontal line). 5 Extrapolation of the rates of memory decline in this study suggest that the Ab1 CN e4 carriers would develop clinically significant memory impairment approximately 10 years after their first assessment (figure 2; see table 1 for baseline demographic characteristics of this group). In contrast, Ab1 CN e4 noncarriers would require 27 years to reach the same criterion. Consistent with these estimates of a relatively slow decline in cognition, only 18% of the Ab1 CN group were classified as having met clinical criteria for MCI or AD over the study period of 72 months, and this proportion was only slightly greater in e4 carriers (22%) than in noncarriers (15%) ( figure 1) . These data reflect the subtlety of Ab-related cognitive decline observed in current preclinical AD groups and suggest that study over even longer intervals may be required to determine the effect of APOE e4 carriage on clinical progression in Ab1 CN older adults.
There is increasing evidence from both human and animal studies that the apoE4 isoform affects risk for AD by disrupting Ab clearance relative to the other apoE isoforms (i.e., apoE3 and apoE2). 7, 8, 20, 21 Further, apoE4 itself has also been implicated directly in neurodegeneration and reduced synaptic integrity, 22 such that even a modest increase in apoE4 levels can increase Ab accumulation and exacerbate synaptic loss around plaques. 23 However, it is not clear whether the processes by which apoE4 affects risk for AD are through an increase in neurotoxicity, loss in neuroprotective function, or combination of both. 21 While the processes by which apoE4 increases risk for AD may occur independently of Ab, it is also likely that Ab oligomers can further impair the physiologic functions of apoE in promoting synaptic and neuronal integrity. 24 Thus, the absence of the APOE e4 allele may afford some level of protection against AD-related neurodegeneration even when the amyloid cascade has begun (i.e., Ab accumulation). The substantial delay in Ab-related memory impairment observed in the current CN group suggests that understanding and manipulating the biological processes by which apoE4 exacerbates Ab toxicity could provide important insight into the pathogenesis of AD and perhaps even a basis for the development of pharmacotherapies to reduce this toxicity and its clinical consequences. The observation in the current study that e4 carriage accounted for more than 18% of additional variance in Ab-related cognitive decline suggests strongly that clinical trials of preclinical AD should consider stratification of their Ab1 samples according to APOE e4 carriage.
While the risk for AD and high levels of Ab posed by APOE e4 carriage have now been documented consistently, 10, 25 the results of this study suggest that in the absence of Ab, APOE e4 carriage does not increase risk for cognitive decline. Despite the comparatively large sample, the long period of investigation, and the sensitive neuropsychological tasks used, we observed no effect of e4 carriage on cognitive decline independent of Ab1. All aspects of cognitive function remained stable in Ab2 CN e4 carriers, and the rate of change of Ab2 CN e4 carriers over the 72-month test-retest period was indistinguishable from that of Ab2 CN e4 noncarriers (figure 2 and table 2). The observation that in Ab2, e4 carriage is not associated with any cognitive decline has been reported previously in the AIBL and other cohorts of CN older adults whose Ab status is known. [4] [5] [6] While a series of large and well-designed prospective studies have shown that carriage of the APOE e4 allele is associated with increased decline in cognitive function, a major limitation of these studies has been that the Ab status of their samples was unknown. 26 It is therefore likely that the decline in cognitive function observed previously in e4 carriers reflected the effects of both Ab1 and e4 carriage, rather than any independent effect of e4 by itself.
When considering the results of this study, an important caveat is that the AIBL study, like many other natural history early AD cohorts, 27, 28 is not a population-based sample. In AIBL, few CN older adults had existing or untreated medical, neurologic, or psychiatric illnesses and most participants were highly educated. As such, it will be important for the results of the current study to be replicated in other early AD cohorts, especially in study groups whose ascertainment has been based on epidemiologic principles (e.g., the Mayo Clinic Study of Aging). 29 A second caveat is that participants underwent neuroimaging at varying timepoints after their baseline assessment, with the median delay between neuropsychological testing and Ab neuroimaging 3 years. However, as current empirical models of AD have shown that the rate of Ab accumulation is very slow, particularly in the preclinical stage of the disease, 3, 30 it is unlikely that individuals classified as Ab1 at the 36month assessment were Ab2 at the baseline assessment. To test this assumption, the main statistical models were recomputed with the time lag between baseline neuropsychological assessment and PET scan entered as a covariate. This reanalysis revealed no statistically significant effect for the time lag (table e-1 on the Neurology ® Web site at Neurology.org). Further, estimates of slopes for each Ab/e4 group also did not change substantially. We now await the completion of sequential amyloid scans in the entire AIBL CN cohort so as to appreciate, more accurately, the relationship between cognitive change and Ab accumulation in e4 carriers and noncarriers. Nonetheless, it will be prudent for future studies to determine whether individuals who transition from Ab2 to Ab1 show a different cognitive profile vs those who remain Ab2 or Ab1 across a study period. However, our current data suggest that the additive effect of Ab1 and e4 on cognitive decline in preclinical AD may make an ideal target for pharmaceutical therapies that mitigate Abrelated neurodegeneration, or from the interaction between Ab1 and e4. They further support the hypothesis that reducing the toxic effects of apoE4 or restoring the neuroprotective functions of apoE isoforms in promoting synaptic plasticity and reducing neuroinflammation may be viable therapeutic strategies for the future. 21 
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